trazodone has been researched along with DDPAC in 1 studies
Trazodone: A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309)
trazodone : An N-arylpiperazine in which one nitrogen is substituted by a 3-chlorophenyl group, while the other is substituted by a 3-(3-oxo[1,2,4]triazolo[4,3-a]pyridin-2(3H)-yl)propyl group.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Halliday, M | 1 |
| Radford, H | 1 |
| Zents, KAM | 1 |
| Molloy, C | 1 |
| Moreno, JA | 1 |
| Verity, NC | 1 |
| Smith, E | 1 |
| Ortori, CA | 1 |
| Barrett, DA | 1 |
| Bushell, M | 1 |
| Mallucci, GR | 1 |
1 other study available for trazodone and DDPAC
| Article | Year |
|---|---|
Repurposed drugs targeting eIF2α-P-mediated translational repression prevent neurodegeneration in mice.
Topics: Animals; Behavior, Animal; Chalcones; Disease Models, Animal; eIF-2 Kinase; Frontotemporal Dementia; | 2017 |